Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02360475 · ClinicalTrials.gov registry record · Phase 2
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 507
- Enrollment target
NCT02360475 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 507 participants.
The verdict
NCT02360475, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 507 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of different formulations of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged 18 to 45 years.
Interventions
- BIOLOGICAL Boostrix
- BIOLOGICAL RSV vaccine GSK3003895A (formulation 1)
- BIOLOGICAL RSV vaccine GSK3003898A (formulation 2)
- BIOLOGICAL RSV vaccine GSK3003899A (formulation 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2015-03-20 |
| Est. Completion | 2016-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02360475
The ClinicalTrials.gov registry entry for NCT02360475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Boostrix is the first listed.
NCT02360475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02360475 about?
NCT02360475 is a clinical study titled "Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women". The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of different formulations of a single intramuscular dose of GSK Biologicals' investigational RSV vaccine, in healthy, non-pregnant women aged 18 to 45 years.
What is the current status of trial NCT02360475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 507 participants. The study started on 2015-03-20. Estimated completion is 2016-06-21.
What interventions are being tested in trial NCT02360475?
The interventions under investigation include: Boostrix (BIOLOGICAL), RSV vaccine GSK3003895A (formulation 1) (BIOLOGICAL), RSV vaccine GSK3003898A (formulation 2) (BIOLOGICAL), RSV vaccine GSK3003899A (formulation 3) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02360475?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.